Palvella Therapeutics (PVLA) Projected to Post Quarterly Earnings on Thursday

Key Points

• Palvella Therapeutics (NASDAQ: PVLA) is set to release its Q2 2025 earnings results on August 13th, with analysts projecting a loss of ($0.81) per share for the quarter.
• The company's share price recently opened at $37.52, with a market cap of $414.97 million and a P/E ratio of -3.10.
• Palvella Therapeutics has received multiple "buy" ratings from analysts, with a consensus price target of $52.22 and several target prices reaching as high as $90.00.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.40) by $2.66. On average, analysts expect Palvella Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Palvella Therapeutics Price Performance

NASDAQ PVLA traded up $1.85 during trading hours on Friday, reaching $40.90. The company's stock had a trading volume of 106,508 shares, compared to its average volume of 187,830. The firm has a fifty day simple moving average of $28.49 and a 200-day simple moving average of $24.31. The stock has a market cap of $452.35 million, a P/E ratio of -3.38 and a beta of -0.01. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $41.00.

Institutional Trading of Palvella Therapeutics

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. acquired a new stake in Palvella Therapeutics in the 1st quarter valued at $533,000. Geode Capital Management LLC grew its position in Palvella Therapeutics by 84.7% in the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company's stock valued at $3,923,000 after purchasing an additional 79,787 shares during the period. Finally, Millennium Management LLC acquired a new stake in Palvella Therapeutics in the 1st quarter valued at $7,553,000. Institutional investors and hedge funds own 40.11% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on PVLA shares. Raymond James Financial started coverage on shares of Palvella Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $54.00 price objective for the company. Truist Financial began coverage on shares of Palvella Therapeutics in a report on Monday, July 21st. They set a "buy" rating and a $56.00 price target for the company. Lifesci Capital began coverage on shares of Palvella Therapeutics in a research note on Monday, August 4th. They issued an "outperform" rating and a $90.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group reduced their price objective on shares of Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Nine equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Palvella Therapeutics presently has a consensus rating of "Buy" and an average target price of $52.40.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.